Thrombin and fibrillar collagen are potent activators of platelets at sites of vascular injury. Both agonists cause platelet shape change, granule secretion, and aggregation to form the primary hemostatic plug. Human platelets express two thrombin receptors, protease-activated receptors 1 and 4 (PAR1 and PAR4) and two collagen receptors, the ␣ 2 ␤ 1 integrin (␣ 2 ␤ 1 ) and the glycoprotein VI (GPVI)/FcR␥ chain complex. Although these receptors and their signaling mechanisms have been intensely studied, it is not known whether and how these receptors cooperate in the hemostatic function of platelets. This study examined cooperation between the thrombin and collagen receptors in platelet adhesion by utilizing a collagen-related peptide (␣2-CRP) containing the ␣ 2 ␤ 1 -specific binding motif, GFOGER, in conjunction with PAR-activating peptides. We demonstrate that platelet adhesion to ␣2-CRP is substantially enhanced by suboptimal PAR activation (agonist concentrations that do not stimulate platelet aggregation) using the PAR4 agonist peptide and thrombin. The enhanced adhesion induced by suboptimal PAR4 activation was ␣ 2 ␤ 1 -dependent and GPVI/FcR␥-independent as revealed in experiments with ␣ 2 ␤ 1 -or FcR␥-deficient mouse platelets. We further show that suboptimal activation of other platelet G q -linked G protein-coupled receptors (GPCRs) produces enhanced platelet adhesion to ␣2-CRP. The enhanced ␣ 2 ␤ 1 -mediated platelet adhesion is controlled by phospholipase C (PLC), but is not dependent on granule secretion, activation of ␣ IIb ␤ 3 integrin, or on phosphoinositol-3 kinase (PI3K) activity. In conclusion, we demonstrate a platelet priming mechanism initiated by suboptimal activation of PAR4 or other platelet G q -linked GPCRs through a PLC-dependent signaling cascade that promotes enhanced ␣ 2 ␤ 1 binding to collagens containing GFOGER sites.
Platelets are small anuclear cellular elements that play a central role in hemostasis and contribute to vascular pathology. At sites of intravascular injury, platelets are exposed to multiple prothrombotic factors that promote thrombus formation and trigger firm adhesion of platelets to the subendothelial extracellular matrix. Thrombin and fibrillar collagen are two of the more potent stimuli (1, 2) .
Thrombin is an essential serine protease in the coagulation cascade that ultimately converts fibrinogen to fibrin. Thrombin also has a direct signaling effect on cells through protease-activated receptors (PARs) 2 , which are G protein-coupled receptors (GPCRs) that are activated by enzymatic cleavage of the N terminus of the receptor to produce a tethered ligand (3) . Of the four known PAR isoforms, human platelets express PAR1 and PAR4. In platelets, these receptors show different signaling kinetics; PAR1 is activated at low thrombin concentrations with a quick signal shutoff, whereas, PAR4 is activated at higher thrombin concentrations with a slow signal shut off (4 -6) . Thrombin-induced signaling has been shown to modulate ligand affinity of the platelet membrane ␣ IIb ␤ 3 integrin (␣ IIb ␤ 3 ) to promote ␣ IIb ␤ 3 activation and induce platelet aggregation (7) (8) (9) . It is still unclear how thrombin activation of PAR1 and/or PAR4 might cooperate with the platelet collagen receptors to influence platelet interactions with collagens.
Platelets are exposed to fibrillar collagens following damage to the vessel wall endothelial cells. Platelets express two receptors for collagens: the ␣ 2 ␤ 1 integrin (␣ 2 ␤ 1 ) and glycoprotein VI (GPVI)/FcR␥ chain complex (10, 11) . Both have important roles in the platelet-collagen interaction. ␣ 2 ␤ 1 is important for stable platelet adhesion under shear stress at the injury site, and GPVI/FcR␥ complex is required for platelet activation (12) (13) (14) (15) . However, there is still considerable debate regarding the precise roles and individual contributions of the two receptors.
The use of collagen-related peptides (CRPs), short peptides that contain repetitive collagen-like sequences (GXXЈ) capable of forming triple helices similar to native collagens, represents a major technical advance in the study of the platelet-collagen interaction. ␣ 2 ␤ 1 has been shown to bind to the consensus sequence GXXЈGER, whereas GPVI binds to the collagen sequence (GPO) n , where n Ն 2 and O is 4-hydroxyproline but not to (GPP) n sequences (16 -18) . For this study, we designed a 42-amino acid CRP (␣2-CRP) that contains the high affinity binding motif for ␣ 2 ␤ 1 , GFOGER, to analyze specifically the platelet ␣ 2 ␤ 1 integrin-collagen interaction.
We show that ␣ 2 ␤ 1 integrin-mediated platelet adhesion is enhanced by suboptimal stimulation (agonist concentrations that do not initiate platelet aggregation) of PAR4, and to a lesser extent PAR1, by PAR-activating peptides or thrombin. We also show that suboptimal activation of other G q -linked GPCRs on platelets (P2Y 1 , TP␣, and TP␤) can stimulate enhanced ␣ 2 ␤ 1 integrin-mediated platelet adhesion. The enhanced platelet adhesion to ␣2-CRP substrate is mediated through a phospholipase C (PLC)-dependent pathway, but not through a PI3K-dependent pathway. Neither activation of ␣ IIb ␤ 3 nor granule secretion is required. We confirm the ␣ 2 ␤ 1 dependence of the process by showing that ␣ 2 ␤ 1 -deficient mouse platelets lose the ability to adhere to ␣2-CRP, whereas both wild-type and FcR␥-deficient mouse platelets exhibit both basal and PAR4-enhanced adhesion.
EXPERIMENTAL PROCEDURES

Materials and Animals
Collagen I from rat-tail tendon was purchased from Upstate Cell Signaling Solutions. ␣2-CRP was synthesized by Celtek Peptides. U73122, U73343, and wortmannin were purchased from Calbiochem. Bovine serum albumin (BSA), MgCl 2 , EDTA, DMSO, PGE 1 , ADP, p-nitrophenol-N-acetyl-␤-D-glucosaminide, RGDS peptide, Apyrase, 3,3Ј,5,5Ј-tetramethylbenzidine dihydrochloride, and other chemicals were purchased from Sigma Aldrich. Activating peptides for PAR1 (PAR1-AP; SFLLRN) and PAR4 (PAR4-AP; AYPGKF) were purchased from GL Biochem. Human ␣-thrombin was purchased from Enzyme Research Labs. U46619 and SQ29,584 were purchased from Cayman Chemical. Anti-human ␣ 2 integrin monoclonal antibody (6F1) was a generous gift from Dr. Barry S. Coller (The Rockefeller University). Anti-human ␣ 2 integrin I-domain monoclonal antibody (12F1) was purchased from BD Pharmingen. Goat anti-mouse secondary antibody conjugated to horseradish peroxidase was purchased from Pierce. Fura2-AM was purchased from Molecular Probes. Hank's Balanced Salt Solution lacking divalent cations (HBSS-) was purchased from Invitrogen. The ␣ 2 integrin subunit-deficient mice, originally generated on a C57Bl/6 ϫ 129/SvJ background were backcrossed 8 times to the C57Bl/6 background using a microsatellite marker-assisted selection ("speed congenics"), as previously described (19) . Knock-out mice for FcR␥ on the C57Bl/6 background were purchased from Jackson Laboratories. Animals were housed in pathogen-free conditions at Vanderbilt University Medical Center in compliance with IACUC regulations. All animals were appropriately age and sex matched.
Methods
Platelet Isolation-Platelet-rich plasma (PRP) and washed platelets from human blood were prepared from blood obtained from healthy volunteers on the day of the experiment according to a protocol approved by the Institutional Review Board as described previously (20) . Murine blood was drawn by cardiac puncture of the left ventricle after carbon dioxide asphyxiation and mixed 10:1 with acid citrate dextrose (ACD; 39 mM citric acid, 75 mM trisodium citrate, 135 mM dextrose) anticoagulant. Mouse platelets were isolated similarly as previously described (19) . Human and mouse platelets were adjusted to 1-4 ϫ 10 8 platelets/ml. Platelet Aggregation-Aggregation assays using PRP were performed on a BIO/DATA Corporation PAP-4 aggregometer at 37°C with stirring (1200 rpm) as described (19) . Agonists were added at designated final concentrations.
Platelet Adhesion-Adhesion assays were carried out using washed, isolated human or mouse platelets (1 ϫ 10 8 platelets/ ml) in the presence of 2 mM MgCl 2 or 5 mM EDTA. Substrates were coated to wells of 96-well Immulon 2HB microtiter plates at a concentration of 30 g/ml unless otherwise denoted and blocked with adhesion buffer. When extracellular inhibitors (Apyrase, SQ29,548, RGDS, or ␣ 2 -inhibitory antibody) or intracellular inhibitors (U73122, U73343, or wortmannin) were used, platelets were treated for 10 min at 21°C before agonist treatment. When agonists (PAR1-AP, PAR4-AP, ADP, U46619, or ␣-thrombin) were used, platelets were treated for 3 min at 21°C. After treatments, platelets were allowed to adhere to the substrates for 60 min unless otherwise denoted at 37°C. Wells were vigorously washed with adhesion buffer plus 2 mM MgCl 2 or 5 mM EDTA, and images of adherent platelets were taken using a Nikon Eclipse TS100 microscope with a Nikon Coolpix P5000 digital camera. Adherent platelets were quantified by a hexosaminidase colorimetric assay using 3.75 mM p-nitrophenol-N-acetyl-␤-D-glucosaminide as the substrate as previously described (20) . The chromogenic reactions were stopped by adding 1.5 volumes of 50 mM glycine, 5 mM EDTA (pH 10.4) buffer, and the well absorbances were read at 405 nm using a Molecular Devices Emax microplate reader. Each data point was performed in triplicate measurements.
Calcium Mobilization-Changes in intracellular calcium concentrations were measured as described previously (21) . Briefly, washed isolated human platelets were incubated with 2.5 M Fura2-AM at 37°C for 30 min and washed. Platelets were resuspended in Tyrodes buffer, and agonist-stimulated calcium mobilization was assayed at 37°C with stirring using a Varian Eclipse fluorometer to measure fluorescence intensity changes at excitation wavelengths of 340 and 380 nm.
Cloning, Expression, and Purification of ␣ 2 Integrin I-domains-The cloning and expression of the ␣ 2 integrin I-domain was similar to our previously described methods (22) . A cDNA encoding the ␣ 2 integrin I-domain (P141-G337) was amplified by PCR, and cloned into pGEX-5X-1 (GE Healthcare) between BamHI and XhoI sites. QuikChange mutagenesis (Stratagene) was used to replace the factor Xa cleavage site with the human rhinovirus 14 3C protease cleavage site (23) . The GST fusion protein was purified on glutathione-Sepharose FF following the manufacturer's instructions (GE Healthcare). The purified fusion protein was cleaved overnight at 4°C in Cleavage Buffer (50 mM Tris-HCl, pH 7.0, 0.15 M NaCl, 1 mM EDTA, 1 mM dithiothreitol) containing rhinovirus 14 3C protease (1/50, w/w). The mixture was passed through a second glutathioneSepharose FF column to remove cleaved GST, any remaining uncleaved fusion protein, and 3C protease (also a GST fusion protein). Flow-through fractions containing I-domain were pooled and dialyzed against 50 mM sodium acetate pH 4.5, 1 mM dithiothreitol. The dialyzed material was applied to an SP-Sepharose HP column, washed extensively with 50 mM sodium acetate, pH 4.5, 1 mM DTT, and eluted in a 0 -1 M linear NaCl gradient. The I-domain eluted at ϳ300 mM NaCl. Pooled fractions were dialyzed at 4°C against TBS (50 mM Tris-HCl, pH 7.4, 150 mM NaCl).
␣ 2 I-domain Binding-Recombinant ␣ 2 I-domain binding was determined by a solid-phase binding assay as previously described (24) . Briefly, substrate-coated 96-well plates were prepared as described above, and wells were blocked with Tris-buffered saline (50 mM Tris-HCl, 150 mM NaCl, pH 7.4) with 300 g/ml BSA. Purified recombinant ␣ 2 I-domain was diluted to 100 nM in wash buffer (Tris-buffered saline containing 0.05% Tween 20, 30 g/ml BSA, and 2 mM MgCl 2 , or 5 mM EDTA) and allowed to bind to the substrates at 21°C. The wells were washed with the appropriate wash buffer, and a 1:500 dilution of anti-␣ 2 I-domain antibody (12F1) in the appropriate wash buffer was added and incubated at 21°C. The wells were washed three times, and a 1:750 dilution of goat anti-mouse IgG secondary antibody conjugated to horseradish peroxidase in the appropriate wash buffer was added and incubated at 21°C. The wells were washed three times, and a solution of tetramethylbenzidine dihydrochloride, prepared according to the manufacturer's instructions, was added to the wells. The chromogenic reactions were stopped with addition of 4 N H 2 SO 4 , and the well absorbances were read at 450 nm using a Molecular Devices Emax microplate reader.
Statistical Analyses-Means, standard deviations (S.D.), standard error of the means (S.E.), two-way ANOVA for column statistics, and nonlinear curve fits were calculated using GraphPad Prism 4 software.
RESULTS
Design and Characterization of the ␣ 2 ␤ 1 -specific Collagenrelated Peptide (␣2-CRP)-To examine the cooperation between thrombin receptors and the collagen receptor, ␣ 2 ␤ 1 integrin, on platelets, we designed a CRP to which ␣ 2 ␤ 1 specifically binds (␣2-CRP) to isolate the integrin-collagen interaction (Fig. 1A) . CRPs have been extensively characterized and are commonly used to analyze platelet interactions with collagen (17) . Based on previous studies, we designed ␣2-CRP to contain a binding sequence for ␣ 2 ␤ 1 (16, 25) . ␣2-CRP was designed as a 42-amino acid peptide containing GPP repeats necessary for triple helix formation and the high affinity ␣ 2 ␤ 1 -specific binding sequence, GFOGER (O is 4-hydroxyproline). GPVI binds specifically to the sequence -(GPO) n -, where n Ն 2, and GPVI loses the ability to bind when the hydroxyproline residues are changed to prolines (16) .
We tested the ability of isolated humanplateletstoadhereinaMg 2ϩ -dependent fashion to ␣2-CRP, collagen I, and BSA substrates (Fig. 1B) . BSA was used as a negative control and showed no platelet adhesion. In the presence of Mg 2ϩ , about 22% of the platelets adhered to collagen I, compared with 11% to ␣2-CRP. In the presence of EDTA, platelets did not adhere to collagen I or ␣2-CRP. Light microscopic analysis of platelets adherent to ␣2-CRP and collagen I substrates showed platelets adhered evenly as a monolayer in the presence of Mg 2ϩ (Fig. 1B) . Platelet aggregates were not present.
To further support the receptor specificity of the ␣2-CRP, we analyzed the effect of an inhibitory monoclonal antibody (6F1) directed against the ␣ 2 ␤ 1 integrin (Fig. 1C) . In the presence of the inhibitory antibody, adhesion to collagen I and ␣2-CRP was largely attenuated. We also determined ␣ 2 ␤ 1 integrin binding specificity by using a purified activated mutant ␣ 2 integrin inserted-domain (E318A ␣ 2 I-domain) (26) . 3 When Mg 2ϩ was present, the E318A ␣ 2 I-domain bound to both collagen I and ␣2-CRP but not to BSA (Fig. 1D) . No I-domain binding was detected when EDTA was present.
Suboptimal PAR Stimulation-PAR1-and PAR4-activating peptides (PAR1-AP and PAR4-AP, respectively) have been well characterized and are important tools used to study the contributions of the two thrombin receptors (9, 27) . The amino acid sequence for PAR1-AP is SFLLRN and for PAR4-AP is AYPGKF. We utilized these specific PAR agonists in preliminary experiments to identify concentrations below which they did not stimulate platelet aggregation in PRP (Fig. 2) . For PAR1-AP, 2.5 M initiated aggregation of about 15% but by 3 min the platelets had disaggregated and returned to baseline; 1 M did not initiate aggregation but could stimulate platelet shape change. For PAR4-AP, 100 M initiated aggregation of about FIGURE 1. Characterization of collagen receptor-specific CRPs. A, the amino acid sequence of the 42-mer CRP designed to bind specifically to ␣ 2 ␤ 1 integrin (␣ 2 ␤ 1 binding motif is underlined). B, platelet adhesion assay to BSA, CNI, or ␣2-CRP using isolated human platelets in the presence of 2 mM MgCl 2 or 5 mM EDTA; on the right, representative microscopic images (40ϫ) of adherent platelets from adhesion assay. C, platelet adhesion assay to BSA, CNI, or ␣2-CRP using isolated human platelets with or without 10 g/ml inhibitory ␣ 2 integrin antibody (6F1). D, ␣ 2 integrin I-domain binding assay using BSA, CNI, or ␣2-CRP as substrates for the recombinant E318A ␣ 2 I-domain. CNI, collagen I; Mg 2ϩ , MgCl 2 . Results are percentages of adherent platelets or absorbances at 450 nm (mean Ϯ S.E. of three independent experiments performed in triplicate).
15% but by 3 min the platelets had disaggregated and returned to baseline; 50 M did not initiate aggregation but could stimulate platelet shape change. We therefore, considered concentrations Յ2.5 M PAR1-AP and Յ100 M PAR4-AP to be suboptimal. In a similar manner, we determined suboptimal concentrations of ␣-thrombin to be Յ1 nM. We also determined suboptimal concentrations for ADP (Յ 500 nM) and a TXA 2 analog, U46619 (Յ 250 nM) (data not shown). To address variability between individual blood donors, we compared PRP from six healthy individuals for their ability to aggregate to 1 M or 20 M PAR1-AP and to 50 M or 200 M PAR4-AP (supplemental Fig. S1A ). For PAR1-AP, the suboptimal concentration (1 M) induced a final mean platelet aggregation of 3.0% Ϯ 3.7, and 20 M produced a final mean aggregation of 81.5% Ϯ 13.1. For PAR4-AP, the suboptimal concentration (50 M) had a final mean platelet aggregation of 1.2% Ϯ 3.0, and 200 M produced a final mean aggregation of 65.5% Ϯ 33.2.
Suboptimal PAR Activation Enhances Platelet Adhesion to ␣2-CRP-Knowing that the suboptimal PAR activation was producing platelet shape change but not aggregation, we analyzed whether this suboptimal stimulation could affect platelet adhesion through ␣ 2 ␤ 1 . To address this, we pretreated isolated human platelets with 1 M PAR1-AP or 50 M PAR4-AP and allowed the platelets to adhere to ␣2-CRP with or without apyrase and SQ29,548 to prevent platelet activation by secreted ADP and TXA 2 , respectively (Fig.  3A) . In the presence and absence of the inhibitors, both 1 M PAR1-AP and 50 M PAR4-AP increased platelet adhesion to ␣2-CRP above basal levels, though the presence of apyrase and SQ29,548 slightly decreased adhesion levels suggesting that some secondary platelet stimulation occurred. We therefore, used apyrase and SQ29,548 treatment in all the following assays unless otherwise specified. The increases in platelet adhesion stimulated by PAR4-AP compared with basal levels were statistically significant (p Ͻ 0.001). To further address variability between individual blood donors, we analyzed the platelets' ability to adhere to the ␣2-CRP in the presence or absence of suboptimal concentrations of the PAR-APs from the same six individuals we analyzed for variance in platelet aggregation (supplemental Fig. S1B ). All of the individuals' platelets showed an increase in adhesion to ␣2-CRP over basal levels when treated with 1 M PAR1-AP or 50 M PAR4-AP, and PAR4 activity produced the greatest increase in adhesion in all donors. Results are percentages of adherent platelets (mean of four independent experiments performed in triplicate). D, time courses for human platelet adhesion were done to analyze changes in platelet adhesion to ␣2-CRP over time when platelets in the presence of apyrase (1 unit/ml) ϩ SQ29,548 (1 M) were treated with 1 M PAR1-AP or 50 M PAR4-AP. Results are percentages of adherent platelets (mean of five independent experiments done in triplicate). E, dose-response curve for a range of ␣-thrombin concentrations in relation to human platelet adhesion to ␣2-CRP in the presence of apyrase (1 unit/ml) ϩ SQ29,548 (1 M). Results are percentages of adherent platelets (mean Ϯ S.E. of three independent experiments each done in triplicate). CNI, collagen I; Apyr, Apyrase; SQ, SQ29,548.
To show that the increase in platelet adhesion to the CRP substrate was not caused by activation of ␣ IIb ␤ 3 integrin (␣ IIb ␤ 3 ) and adhesion of platelet aggregates, we determined whether inhibiting ␣ IIb ␤ 3 by using a small peptide, RGDS, affected the enhanced platelet adhesion to ␣2-CRP stimulated by 1 M PAR1-AP or 50 M PAR4-AP (Fig. 3B) . The presence of RGDS did not affect the enhancement of platelet adhesion to ␣2-CRP stimulated by 1 M PAR1-AP or 50 M PAR4-AP. The increases in platelet adhesion stimulated by PAR4-AP compared with basal levels were statistically significant (p Ͻ 0.05). This finding was consistent with our microscopic examination showing the absence of platelet aggregates (data not shown).
We further analyzed the PAR-stimulated enhancement of platelet adhesion to ␣2-CRP by dose-response and time-course analyses. The dose-response curves for PAR1-AP and PAR4-AP enhancement (Fig. 3C) show that a range of suboptimal concentrations for both PAR1-AP and PAR4-AP can stimulate greater adhesion of platelets to ␣2-CRP. Suboptimal stimulation of PAR4 produces a greater maximal enhancement than does PAR1. PAR4-AP initiated enhancement of platelet adhesion at 1 M and had a maximum enhancement of 2.1-fold at 100 M. PAR1-AP started to show enhancement of platelet adhesion at 0.1 M and had a maximum enhancement of 1.7-fold at 5 M. This difference between PAR1 and PAR4 is also evident in the time-course analysis (Fig. 3D) . We examined adhesion of PAR1-AP (1 M) or PAR4-AP (50 M) treated platelets to ␣2-CRP over 60 min, and we observed that PAR4-AP-treated platelets exhibited an increased rate of adhesion to ␣2-CRP compared with PAR1-AP-treated and -untreated platelets. PAR1-AP treatment had a minimal increase in rate of platelet adherence compared with the basal rate. To link this PAR activity to their physiological activator, thrombin, we determined the dose-response curve for ␣-thrombin in relation to platelet adhesion to ␣2-CRP (Fig.  3E) . Previously, we determined suboptimal concentrations of ␣-thrombin to be Յ1 nM (Fig. 2) . We then used a range of suboptimal concentrations of ␣-thrombin to treat platelets and analyze their adhesion to ␣2-CRP, and we show 0.1 and 1 nM ␣-thrombin can also stimulate enhancement of platelet adhesion to the CRP. Interestingly, the enhancement decreased at the highest concentration (10 nM) of thrombin tested.
Enhanced Platelet Adhesion to ␣2-CRP Is PLC-dependent and Is Also Induced by Other Platelet G qlinked GPCRs-Because both PAR1 and PAR4 can link and signal through the G-protein G q , we analyzed suboptimal PAR activation by determining if 1 M PAR1-AP or 50 M PAR4-AP could stimulate intracellular Ca 2ϩ mobilization (Fig. 4A ). Both 1 M PAR1-AP and 50 M PAR4-AP stimulated intracellular Ca 2ϩ mobilization with the PAR4 response being greater and longer in duration than PAR1. 1 M PAR1-AP resulted in a limited extent of calcium mobilization compared with that produced by 20 M PAR1-AP, whereas, 50 M PAR4-AP stimulated a calcium mobilization similar to that produced by 200 M PAR4-AP in intensity but which was not sustained over time. 10 nM thrombin was used as a positive control.
Because suboptimal activation of both PAR1 and PAR4 stimulated intracellular Ca 2ϩ mobilization, we determined whether these GPCRs were producing the enhanced platelet adhesion via G q and PLC␤2/␤3 signaling pathway (Fig. 4B ). Platelets treated with the solvent (DMSO) maintained enhanced adhesion when stimulated by 1 M PAR1-AP or 50 M PAR4-AP. When platelets were treated with 10 M U73122, a PLC inhibitor, the enhanced platelet adhesion stimulated by 1 M PAR1-AP or 50 M PAR4-AP was attenuated and decreased to basal levels. When platelets were treated with 10 M U73343, a U73122 negative control molecule (differs from U73122 by an absence of a double bond), the enhanced platelet adhesion stimulated by 1 M PAR1-AP or 50 M PAR4-AP remained intact. We also determined if PI3K played a role in the enhanced platelet adhesion using the PI3K inhibitor, wortmannin. When platelets were treated with 100 nM wortmannin the enhanced platelet adhesion stimulated by 1 M PAR1-AP or 50 M PAR4-AP was not affected.
The ADP receptor, P2Y1, and the TXA 2 receptors, TP␣ and TP␤, are also platelet GPCRs that signal through G q proteins. To investigate their effects on platelet adhesion to ␣2-CRP, we employed an approach similar to that which we used to study the PAR receptors except apyrase and SQ29,548 were excluded from the adhesion assay. We determined suboptimal concen- trations of ADP and U46619 (a TXA 2 analog) to be 500 nM and 250 nM, respectively (data not shown). Platelets in the absence of apyrase and SQ29,548 showed enhanced adhesion compared with basal when stimulated by 1 M PAR1-AP, 50 M PAR4-AP, 500 nM ADP, or 250 nM U46619 (Fig. 4C) . When platelets were treated with 10 M U73122, the enhanced platelet adhesion stimulated by 1 M PAR1-AP, 50 M PAR4-AP, 500 nM ADP, or 250 nM U46619 was attenuated, but platelets still bound at basal levels.
PAR4 Stimulated Enhanced Adhesion of Mouse Platelets-To further support a PAR-driven priming mechanism for enhanced ␣ 2 ␤ 1 integrin-mediated adhesion, we analyzed the adhesion of platelets from wild-type (␣ 2 ϩ/ϩ), ␣ 2 ␤ 1 -deficient (␣Ϫ/Ϫ) and FcR␥-deficient (␣ 2 ϩ/ϩ FcR␥Ϫ/Ϫ) mice on the pure C57Bl/6 background to collagen I and ␣2-CRP (Fig. 5) . First, we determined adhesion levels to BSA, collagen I, or ␣2-CRP by wild-type, ␣2-deficient, or FcR␥-deficient mouse platelets (Fig. 5A) . Both wild-type platelets and FcR␥-deficient platelets adhered to collagen I and ␣2-CRP, but platelet adhesion to the substrates was completely lost in ␣2-deficient platelets. No platelet adhesion was seen on BSA substrates. Next, we analyzed the effect of suboptimal activation of PAR4 (mice do not express PAR1 on platelets) on wild-type, ␣2-deficient, or FcR␥-deficient mouse platelets on adhesion to ␣2-CRP (Fig.  5B) . Similar to human platelets, treatment of wild-type mouse platelets with 50 M PAR4-AP did not produce platelet aggregation and was determined to be suboptimal (data not shown). Wild-type, ␣2-deficient, or FcR␥-deficient mouse platelets were treated with 50 M PAR4-AP, 1 M PAR1-AP (negative control), or vehicle and adhesion to ␣2-CRP was measured. Wild-type platelets showed a basal level of adhesion when treated with vehicle or 1 M PAR1-AP, but when treated with 50 M PAR4-AP, platelet adhesion substantially increased. ␣2-deficient platelets exhibited no adhesion even when treated with 50 M PAR4-AP. FcR␥-deficient platelets showed adhesion similar to that of wild-type platelets. They adhered at a basal level when treated with vehicle, but with 50 M PAR4-AP treatment, platelet adhesion increased markedly. The PAR4-AP stimulated enhancement of wild-type and FcR␥-deficient platelets to ␣2-CRP was abolished by the PLC inhibitor, U73122 (Fig. 5B) . These experiments were also carried out with wild-type (␣ 2 ϩ/ϩ), ␣ 2 ␤ 1 -deficient (␣Ϫ/Ϫ), and GPVIdeficient (␣ 2 ϩ/ϩ GPVIϪ/Ϫ) mice on a mixed background (C57Bl/6 ϫ 129/SvJ). The results of these studies were entirely concordant with those presented above for mice on the pure C57Bl/6 background (data not shown).
DISCUSSION
This study provides further insight into the mechanisms giving rise to stable adhesion of platelets to collagen at sites of vascular injury. The data reveal cooperation between the platelet receptors for thrombin, ADP, and TXA 2 with the collagen receptor, ␣ 2 ␤ 1 integrin. Specifically, the results show that suboptimal stimulation of PAR4, and other platelet G q -linked GPCRs (P2Y 1 , TP␣/␤, and to a lesser degree PAR1) can trigger a PLC-dependent priming mechanism of ␣ 2 ␤ 1 integrin that enhances platelet adhesion to collagen. This GPCR-mediated enhancement of platelet adhesion through the ␣ 2 ␤ 1 integrin suggests the presence of an additional, novel GPVI-independent mechanism to the multistage model of platelet adhesion to collagen at vascular injury sites.
For this study, we utilized the ␣2-CRP as a platelet adhesion substrate that exclusively utilizes the ␣ 2 ␤ 1 integrin-specific interaction (GFOGER) and mimics the triple-helical structure of collagens while eliminating the GPVI/FcR␥ complex interaction and other indirect platelet-collagen interactions. This separation of interactions was necessary because the individual roles of ␣ 2 ␤ 1 integrin and GPVI/FcR␥ complex during platelet collagen adhesion and their relevance in hemostasis have been debated intensely (18, 28 -30) . The GFOGER sequence is primarily found in collagens I, II, and IV, which are constituents of the vascular subendothelial extracellular matrix (17) . ␣2-CRP supported ␣ 2 ␤ 1 integrin-specific binding with a metal ion-dependence consistent with previous studies utilizing similar CRPs (17, 31, 32) . Using the ␣2-CRP substrate, we demonstrated that suboptimal concentrations of PAR1-AP, PAR-4AP, ␣-thrombin, ADP, and U46619 enhanced platelet adhesion mediated by the ␣ 2 ␤ 1 integrin. Suboptimal PAR activation enhanced platelet adhesion independently of platelet secretion or ␣ IIb ␤ 3 integrin activation. The apparent activation of ␣ 2 ␤ 1 integrin and not ␣ IIb ␤ 3 integrin was surprising and suggests there are different activation mechanisms or differences in the threshold for activation between these two platelet integrins.
Our observations and conclusions are consistent with evidence presented by others. Jung and Moroi (33, 34) showed enhanced binding of soluble collagen III by platelets stimulated with optimal concentrations of thrombin, ADP, and U46619. Siljander et al. (31) showed enhanced platelet adhesion to CRPs containing various lower affinity GXXGER motifs upon stimulation with ADP. Furthermore, Inoue et al. (32) showed ADP enhanced adhesion and spreading of FcR␥-deficient mouse platelets to a GFOGER containing CRP. Our data indicate that this enhancing or priming effect on platelet adhesion to collagen may be mediated by several different platelet GPCRs and occurs without full activation of the GPCR. The combined use of the CRP specific for the ␣ 2 ␤ 1 integrin and of platelets deficient in GPVI/FcR␥ expression has allowed us to demonstrate that the enhanced adhesion to collagen results from an effect on the ␣ 2 ␤ 1 integrin and that GPVI/FcR␥ is not required, either directly or indirectly, for the adhesion enhancing effect.
To understand how suboptimally activated PAR1 and PAR4 transmit signals to enhance ␣ 2 ␤ 1 integrin-mediated platelet adhesion, we analyzed whether the signal transductions were through the G q pathway of PLC activation shared by these GPCRs. Analysis of platelets treated with optimal PAR1-AP, PAR4-AP, and thrombin verified intracellular Ca 2ϩ mobilization and showed the expected differences between the kinetics of PAR1 and PAR4, in agreement with previous studies (4, 6) . A dramatic difference in intracellular Ca 2ϩ mobilization was observed between suboptimal PAR1-AP and PAR4-AP; whereas 1 M PAR1-AP produced weak calcium mobilization, 50 M PAR4-AP resulted in a level of calcium mobilization similar to that produced by 200 M of the activating peptide except the mobilization was not sustained. The calcium mobilization correlated with the levels of enhanced adhesion produced by each PAR and suggested that PLC was being activated to induce the enhancement. Inhibition of PLC with U73122 completely eliminated the PAR-enhanced adhesion, but left the basal level of adhesion unaltered. In contrast, inhibition of PI3K had no effect on the enhancement of platelet adhesion. This latter observation is in contrast with the report of Jung et al. (34) who observed in their analysis of activated platelet binding of soluble collagen III a dependence upon PI3K. This discrepancy may be caused by fundamental differences between platelet adhesion to solid-phase substrates and the binding of soluble ligands as observed by our group and others (32) . These data support a GPCR-mediated ␣ 2 ␤ 1 integrin priming mechanism for platelet adhesion to collagen through PLC. Other molecules involved in the priming mechanism remain to be determined. Future studies might provide insight into whether the enhanced adhesion is due to a change in affinity or avidity of ␣ 2 ␤ 1 integrin for collagen. Both PAR1 and PAR4 are able to stimulate enhanced platelet adhesion to ␣2-CRP, but PAR4 is more effective. This could be attributed to the different signaling kinetics of PAR1 and PAR4 as evident in the intracellular Ca 2ϩ mobilization data and supported by previous studies (5, 6) . Suboptimal concentrations of ␣-thrombin, the physiologic agonist of PAR1 and PAR4, also stimulated enhanced platelet adhesion to ␣2-CRP. The level of enhanced adhesion observed with suboptimal thrombin stimulation resembles that observed with PAR4, suggesting further cooperation between PAR1 and PAR4 on human platelets. Similar to PAR3 on mouse platelets, PAR1 may serve as a cofactor for PAR4 activation by thrombin as shown previously because of their ability to heterodimerize (35) (36) (37) . Interestingly, the thrombin dose-response curves show less enhancement of adhesion at the highest concentration tested (10 nM). This could be due to PAR desensitization and internalization. Alternatively or additionally, inhibition of thrombin by platelet-secreted factors (antithrombin) may contribute (38) .
These data suggest that suboptimal activation of platelets by thrombin through PAR1 and PAR4 at vascular injury sites can prime platelets to adhere more avidly to collagens that contain the GFOGER binding sequence and in theory to other GXXGER sequences in collagens (18) . This mechanism is further supported by the recent findings regarding the role of thrombin in platelet adhesion to collagen under conditions of flow. Van der Meijden et al. (39) described separate but complimentary roles of thrombin produced subsequent to the contact activation of factor XII by collagen, and GPVI/FcR␥ signaling on human platelet adhesion to collagen. Furthermore, inhibition of thrombin resulted in diminished platelet adhesion to collagen. Mangin et al. (40) reported that thrombin was able to compensate for the effect of GPVI/FcR␥ deficiency in mouse platelets in in vivo models of thrombosis. The mechanism we describe, selective enhancement of the adhesive activity of the ␣ 2 ␤ 1 integrin via PAR4 activation, is the likely explanation for the observations of van der Meijden et al. (39) and Mangin et al. (40) .
Our group originally proposed a two-step, two-site model of platelet adhesion and activation to collagen in which the higher affinity collagen receptor, ␣ 2 ␤ 1 integrin, binds first followed by the subsequent engagement of a lower affinity, signal-transducing co-receptor (41) , which was shown to be the GPVI/FcR␥ complex (42, 43) . There has been much debate regarding the roles of ␣ 2 ␤ 1 integrin and GPVI/FcR␥ complex in the two-step, two-site model (44, 45) . It has been suggested that engagement of GPVI may be required for activation of the ␣ 2 ␤ 1 integrin (29, 44, 45) . We have previously shown that platelets from ␣ 2 ␤ 1 -deficient mice have delayed thrombus formation in vivo within the carotid artery (12) , and that under flow conditions in vitro, GPVI/FcR␥ complex and ␣ 2 ␤ 1 integrin both play independent and vital roles in platelet adhesion and aggregation to collagen (46) . Data from the present study suggest that platelets exposed to low levels of thrombin, ADP, or TXA 2 prior to contact with collagen at sites of vascular injury would have an increased affinity or avidity toward exposed ␣ 2 ␤ 1 integrin binding sites on collagens as a result of inside-out activation of ␣ 2 ␤ 1 integrin induced by GPCR signals through PLC to promote more stable adhesion. This supports an alternate, GPVI/FcR␥-independent pathway toward stable adhesion of platelets to collagen at sites of vascular injury. Future studies under in vitro or in vivo flow conditions will be necessary to test this GPCR priming mechanism of ␣ 2 ␤ 1 integrin. A recent report (47) supports the concept. In summary, we have shown that suboptimal activation of the thrombin receptors and other G q -linked GPCRs can enhance adhesion through ␣ 2 ␤ 1 integrin to GFOGER sites of collagens via a PLC-dependent priming mechanism. The data shed new light on the contributions that GPCRs and PLC signaling make toward platelet integrin-extracellular matrix interactions and could have implications in the design and application of novel therapeutic agents that target platelet GPCRs.
